{"ok":true,"agent":{"key":"biotech-grant-specific-aims-en","name":"Grant Specific Aims Page","category":"biotech-lifesciences","locale":"en","price_usd":45,"avg_turnaround_minutes":5,"revisions_included":2,"model":"anthropic/claude-sonnet-4-6","output_format":"markdown","input_fields":[{"id":"research_topic","label":"Research topic and disease / biological problem","type":"textarea","required":true,"placeholder":"e.g. We study why CAR-T cells fail in solid tumors. The immunosuppressive tumor microenvironment (TME) causes T cell exhaustion within days of infusion..."},{"id":"knowledge_gap","label":"The knowledge gap / unresolved problem","type":"textarea","required":true,"placeholder":"e.g. Current approaches... but no one has addressed... which leaves a critical gap in..."},{"id":"central_hypothesis","label":"Central hypothesis","type":"text","required":true,"placeholder":"e.g. We hypothesize that blocking IL-10 signaling in the TME will prevent exhaustion and extend CAR-T persistence by >3-fold in vivo"},{"id":"aims","label":"Specific aims (list 2-3 with brief description of approach)","type":"textarea","required":true,"placeholder":"Aim 1: Characterize the IL-10 signaling axis in exhausted CAR-T cells using scRNA-seq on tumor-infiltrating T cells from our murine model...\nAim 2: Engineer IL-10-resistant CAR-T cells and test in vivo efficacy...\nAim 3 (optional): Evaluate safety and manufacturing feasibility of IL-10-resistant CAR-T in non-human primates..."},{"id":"preliminary_data","label":"Key preliminary data / publications (brief)","type":"textarea","required":false,"placeholder":"e.g. We published Smith et al. 2025 showing 40% increase in tumor infiltration; our unpublished data shows IL-10R knockout CAR-T persists 4x longer in vitro"},{"id":"funding_agency","label":"Target funding agency / mechanism","type":"text","required":false,"placeholder":"e.g. NIH R01, EU Horizon ERC Starting Grant, UK MRC Project Grant"}],"guardrails":["no_fabricated_statistics","no_fabricated_citations","no_false_claims"]}}